Mesoblast shares (ASX: MSB) sat atop the ASX 200 gainers board today, closing 4.91% higher at A$2.35 to continue an impressive two-week rally that has seen the stock rebound 24%.
The MSB share price has now recovered substantially from recent lows, with the two-week rebound reflecting a notable shift in sentiment toward the company’s commercial and regulatory prospects.
Driving the rebound in Mesoblast
Multiple developments appear to be converging to support the current upward momentum. Bell Potter recently upgraded Mesoblast to Buy, maintaining a price target of A$4.45, implying potential upside of approximately 89% from current levels.
The brokerage upgrade comes against a backdrop of meaningful operational progress. On June 25, 2026, Mesoblast announced it had drawn US$50 million from a five-year non-dilutive financing facility, effectively extending the company’s cash runway without triggering immediate shareholder dilution. For a development-stage biotech, such financing represents a critical de-risking event, addressing one of the market’s longstanding concerns about the company’s capital structure.
Perhaps most significantly, Mesoblast has been advancing regulatory interactions around Ryoncil (remestemcel-L), its lead asset targeting steroid-refractory acute graft versus host disease. A June 30, 2026 update outlined progress on the company’s biologics license application with the U.S. Food and Drug Administration, while a July 9 release highlighted positive developments reinforcing Ryoncil’s status as the cornerstone of the company’s inflammatory disease portfolio.
Top Australian Brokers
- Pepperstone - Top Australian broker - Read our review
- eToro - Invest in ASX and international shares - Read our review
Broker Support Builds Momentum
Beyond Bell Potter’s bullish stance, Mesoblast has attracted supportive coverage from multiple research houses. Canaccord Genuity maintains a Buy rating with a price target around A$2.97, while the company’s NASDAQ-listed shares (ticker: MESO) similarly enjoys predominantly positive analyst sentiment. This clustering of Buy recommendations creates a supportive backdrop for continued price appreciation, particularly as short sellers potentially unwind positions.
Market sentiment has clearly shifted from the cautious scepticism that characterised earlier periods, particularly following previous regulatory setbacks. The combination of tangible progress on the regulatory front, improved capital structure, and visible broker endorsement appears to have created a self-reinforcing positive feedback loop, at least in the near term.
What next?
Looking ahead, markets will be focused on concrete regulatory milestones, particularly any formal FDA communications regarding the Ryoncil BLA and timelines toward potential approval. Trial readouts for follow-on indications and updates on commercial strategy will also factor into the evolving investment narrative.
Analyst consensus suggests meaningful upside remains from current levels, though the magnitude of that potential return depends heavily on execution against a complex regulatory and commercial roadmap. The company’s ability to convert recent positive momentum into sustained value creation will ultimately hinge on transforming regulatory progress into approved products and, eventually, revenue generation.
